4 ms·

Lots of potential questions here, but let's start with three: - What makes you "better" than your competitors, perhaps especially those of your competitors wit

Lots of potential questions here, but let's start with three: - What makes you "better" than your competitors, perhaps especially those of your competitors with substantially deeper pockets than you ? (e.g. Apple Watch which also has "ECG" functionality). - Building on the above, how's the prior art looking on the patents ? - Finally, general cynicism on "home ECG".... clinical evaluation is 12 lead ECG. Can you really get away with substantially less input ? (Garbage In - Garbage Out).

Rssnkgp02 5y ago
Great questions. The Apple Watch is a single lead, so doesn't have the resolution to do the computations. Also, the algorithms aren't trivial for automation this, but the data moat is extremely important for capturing and appropriately testing this population. There is prior art, which our own filing took into accout. Lastly, the hardware devices we use are all FDA approved to measure the appropriate interval, one of which is FDA approved 12-lead ECG patch approved for patient self-administration.
- neurotech1 5y ago
  That and the Apple Watch is on the wrist, which could introduce artifact to the ECG. There are single lead chest ECG patches used for specific diagnostic reasons. Zio patch is one common device used. [0] [0] https://www.irhythmtech.com/patients/how-it-works https://www.irhythmtech.com/patients/how-it-works
  - traceroute66 5y ago
    > That and the Apple Watch is on the wrist, which could introduce artifact to the ECG. If patent filings are a guide[1], Apple are aware and have been investigating options for user-friendly additional sensors elsewhere on the body. Whether it comes to market is another matter, of course. [1] http://patft1.uspto.gov/netacgi/nph-Parser?patentnumber=11083383 http://patft1.uspto.gov/netacgi/nph-Parser?patentnumber=1108...
    - Rssnkgp02 5y ago
      Good points!
  - Rssnkgp02 5y ago
    Excellent points. Artifact is indeed a tricky problem for EKGs, and the ziopatch is a great device. Generally, multiple leads are needed (ideally 6 or 12 leads) to accurately measure repolarization of the heart.

Rssnkgp02 5y ago

Great questions. The Apple Watch is a single lead, so doesn't have the resolution to do the computations. Also, the algorithms aren't trivial for automation this, but the data moat is extremely important for capturing and appropriately testing this population. There is prior art, which our own filing took into accout. Lastly, the hardware devices we use are all FDA approved to measure the appropriate interval, one of which is FDA approved 12-lead ECG patch approved for patient self-administration.

neurotech1 5y ago
That and the Apple Watch is on the wrist, which could introduce artifact to the ECG. There are single lead chest ECG patches used for specific diagnostic reasons. Zio patch is one common device used. [0] [0] https://www.irhythmtech.com/patients/how-it-works https://www.irhythmtech.com/patients/how-it-works
- traceroute66 5y ago
  > That and the Apple Watch is on the wrist, which could introduce artifact to the ECG. If patent filings are a guide[1], Apple are aware and have been investigating options for user-friendly additional sensors elsewhere on the body. Whether it comes to market is another matter, of course. [1] http://patft1.uspto.gov/netacgi/nph-Parser?patentnumber=11083383 http://patft1.uspto.gov/netacgi/nph-Parser?patentnumber=1108...
  - Rssnkgp02 5y ago
    Good points!
- Rssnkgp02 5y ago
  Excellent points. Artifact is indeed a tricky problem for EKGs, and the ziopatch is a great device. Generally, multiple leads are needed (ideally 6 or 12 leads) to accurately measure repolarization of the heart.